MXBIO is a specialized dental bioventure company dedicated to addressing unmet medical needs in oral healthcare.Approved by the Ministry of Food and Drug Safety (MFDS) in April 2026, PERIMEDI® is Koreas first non-surgical, preion-only combination antibiotic ointment for peri-implantitis and moderate-to-severe periodontitis, formulating Minocycline and Metronidazole.Combining broad-spectrum antibacterial efficacy against both aerobic and anaerobic bacteria with proprietary mucoadhesive formulation technology, PERIMEDI® achieves prolonged retention within the periodontal pocket and rapid drug release. Its exceptional therapeutic efficacy and safety have been demonstrated through Phase 3 clinical trials.Supported by a robust domestic and global distribution network, MXBIO is leading the dental pharmaceutical market.Furthermore, leveraging our proprietary drug delivery technology, we are actively expanding our pipeline and developing diverse innovative products, including veterinary periodontal treatments, topical acne ointments, and functional collagen masks.